Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma

British Journal of Haematology

Volumn 122, Issue 3, 2003, Pages 457-464

  Shimoni, Avichai ^a   Hardan, Izhar ^a   Avigdor, Abraham ^a   Yeshurun, Moshe ^a   Raanani, Pia ^a   Ben Bassat, Isaac ^a   Nagler, Arnon ^a  

^a SHEBA MEDICAL CENTER   (Israel)

Author keywords

Lymphoma; Rituximab; Stem cell transplantation

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DIPHENHYDRAMINE; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; MELPHALAN; METHOTREXATE; PARACETAMOL; RITUXIMAB; THYMOCYTE ANTIBODY;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HYPOGAMMAGLOBULINEMIA; MALE; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; NEUTROPENIA; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0042128617     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2003.04446.x     Document Type: Article

References (34)

1. Buckstein, R., Imrie, K., Spaner, D., Potichnyj, A., Robinson, J.B., Nanji, S., Pennel, N., Reis, M., Pinkerton, P., Dube, I., Hewitt, K. & Berinstein, N.L. (1999) Stem cell function and engraftment is not affected by 'in vivo purging' with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma. Seminars in Oncology, 26, 115-122.
2. Chopra, R., Goldstone, A.H., Pearce, R., Philip, T., Petersen, F., Appelbaum, F., De Vol, E. & Ernst, P. (1992) Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group Registry data. Journal of Clinical Oncology, 10, 1690-1695.
3. Coiffier, B., Haioun, C., Ketterer, N., Engert, A., Tilly, H., Ma, D., Johnson, P., Lister, A., Feuring-Buske, M., Radford, J.A., Capdeville, R., Diehl, V. & Reyes, F. (1998) Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood, 92, 1927-1932.
4. Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., Reyes, F., Lederlin, P. & Gisselbrecht, C. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. New England Journal of Medicine, 346, 235-242.
5. Dhedin, N., Giraudier, S., Gaulard, P., Esperou, H., Ifrah, N., Michallet, M., Milpied, N., Rio, B., Cahn, J.Y., Molina, L., Laporte, J.L., Guilhot, F. & Kuentz, M. for the Societé Francaise de Greffe de Moelle (1999) Allogeneic bone marrow transplantation in aggressive non-Hodgkin's lymphoma (excluding Burkitt and lymphoblastic lymphoma): a series of 73 patients from the SFGM database. British Journal of Haematology, 107, 154-161.
6. Flinn, I.W., O'Donnell, P.V., Goodrich, A., Vogelsang, G., Abrams, R., Noga, S., Marcellus, D., Borowitz, M., Jones, R. & Ambinder, R.F. (2000) Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Biology of Blood and Marrow Transplantation, 6, 628-632.
7. Horwitz, S.M., Negrin, R.S., Stockerl-Goldstein, K.E., Johnston, L.J., Shizuru, J.A., Stuart, M.J., Breslin, S., Blume, K.G. & Horning, S.J. (2001) Phase II trial of rituximab as adjuvant therapy to high-close chemotherapy and peripheral blood stem cell transplantation for relapsed and refractory aggressive non-Hodgkin's lymphoma. Blood, 98, 862a.
8. Jones, R.J., Ambinder, R.F., Piantadosi, S. & Santos, G.W. (1991) Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood, 77, 649-653.
9. Kaplan, E.L. & Meier, P. (1958) Nonparametric estimation from incomplete observations. Journal of the American Statistical Association, 53, 457-481.
10. Kaya, H., Keung, Y.K., Case, D., Cruz, J.M., Perry, J.J., Radford, J.E. & Hurd, D.D. (2002) Efficacy and safety of monoclonal anti-CD20 antibody (rituximab) for the treatment of patients with recurrent low-grade non-Hodgkin's lymphoma after high-dose chemotherapy and autologous hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation, 8, 544-549.
11. Khouri, I.F., Saliba, R.M., Giralt, S.A., Lee, M.S., Okoroji, G.J., Hagemeister, F.B., Korbling, M., Younes, A., Ippoliti, C., Gajewski, J.L., McLaughlin, P., Anderlini, P., Donato, M.L., Cabanillas, F.F. & Champlin, R.E. (2001) Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood, 98, 3595-3599.
12. McLaughlin, P., Grillo-Lopez, A.J., Link, B.K., Levy, R., Czuczman, M.S., Williams, M.E., Heyman, M.R., Bence-Bruckler, I., White, C.A., Cabanillas, F., Jain, V., Ho, A.D., Lister, J., Wey, K., Shen, D. & Dallaire, B.K. (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent Iymphoma: half of patients respond to a four-dose treatment program. Journal of Clinical Oncology, 16, 2825-2833.
13. Maloney, D.G., Smith, B. & Rose, A. (2002) Rituximab: mechanism of action and resistance. Seminars in Oncology, 29, 2-9.
14. Maloney, D.G., Grillo-Lopez, A.J., White, C.A., Bodkin, D., Schilder, R.J., Neidhart, J.A., Janakiraman, N., Foon, K.A., Liles, T.M., Dallaire, B.K., Wey, K., Royston, I., Davis, T. & Levy, R. (1997) IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood, 90, 2188-2195.
15. Mills, W., Chopra, R., McMillan, A., Pearce, R., Linch, D.C. & Goldstone, A.H. (1995) BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. Journal of Clinical Oneology, 13, 588-595.
16. Milojkovic, D., Mijovic, A., Taylor, C.G., Mufti, G.J. & Pagliuca, A. (2000) Rituximab salvage following relapse after allogeneic bone marrow transplantation for non-Hodgkin's lymphoma. British Journal of Haematology, 110, 1013-1014.
17. Mohty, M., Faucher, C., Vey, N., Chabannon, C., Sainty, D., Arnoulet, C., Gangler, B., Gastaut, J.A., Maraninchi, D., Olive, D. & Blaise, D. (2002) Features of large granular lymphocytes (LGL) expansion following allogeneic stem cell transplantation: a long-term analysis. Leukemia, 16, 2129-2133.
18. Nagler, A., Slavin, S., Varadi, G, Naparstek, E., Samuel, S. & Or, R. (2000a) Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transplantation, 25, 1021-1028.
19. Nagler, A., Rabinowitz, R., Rosengolts-Rat, J., Condiotti, R. & Schlesinger, M. (2000b) Natural killer (NK) and T cell-associated surface marker expression following allogeneic and autologous bone marrow transplantation (BMT). Journal of Hematotherapy and Stem Cell Research, 9, 63-75.
20. Pan, D., Moskowitz, C.H., Zelenetz, A.D., Straus, D., Kewalaramani, T., Noy, A., Qin, J., Teruya-Feldstein, J. & Portlock, C.S. (2002) Rituximab for aggressive non-Hodgkin's lymphomas relapsing after, or refractory to, autologous stem cell transplantation. Cancer Journal, 8, 371-376.
21. Papadaki, T., Stamatopoulos, K., Stavroyianni, N., Paterakis, G., Phisphis, M. & Stefanoudaki-Sofianatou, K. (2002) Evidence for T-large granular lymphocyte-mediated neutropenia in rituximab-treated lymphoma patients: report of two cases. Leukemia Research, 26, 597-600.
22. Parkman, R. & Weinberg, K.I. (1999) Immunological reconstitution following hematopoietic stem cell transplantation. In: Hematopoietic Cell Transplantation. (ed. by E.D. Thomas, K.G. Blume & S.J. Forman), pp. 704-711. Blackwell Science, Malden.
23. Philip, T., Armitage, J.O., Spitzer, G., Chauvin, F., Jagannath, S., Calm, J.Y., Colombat, P., Goldstone, A.H., Gorin, N.C., Flesh, M., Laporte, J., Maraninchi, D., Pico, J., Bosly, A., Anderson, C., Schots, R., Biron, P., Cabinillas, F. & Dicke, K. (1987) High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. New England Journal of Medicine, 316, 1493-1498.
24. Philip, T., Guglielmi, C., Hagenbeek, A., Somers, R., Van der Lelie, H., Bron, D., Sonneveld, P., Gisselbrecht, C., Cahn, J.Y., Harousseau, J.L., Coiffier, B., Biron, P., Mandelli, F. & Chauvin, F. (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. New England Journal of Medicine, 333, 1540-1545.
25. Przepiorka, D., van Besien, K., Khouri, I., Hagemeister, F., Samuels, B., Folloder, J., Ueno, N.T., Molldrem, J., Mehra, R., Korbling, M., Giralt, S., Gajewski, J., Donato, M., Cleary, K., Claxton, D., Braunschweig, I., Andersson, B., Anderlini, P. & Champlin, R. (1999) Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. Annals of Oncology, 10, 527-532.
26. Ratanatharathorn, V., Uberti, J., Karanes, C., Abella, E., Lum, L.G., Momin, F., Cummings, G. & Sensenbrenner, L.L. (1994) Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood, 84, 1050-1055.
27. Ratanatharathorn, V., Bociek, R.G., Pavlovic, S.Z., Lynch, J.C., Ferrara, J.L.M. & Uberti, J.P. (2000) Prior therapy with anti-CD20 chimeric antibody (rituximab) may decrease the risk of acute graft-versus-host disease (GVHD) in patients with non-Hodgkin's lymphoma receiving allogeneic transplantation. Blood, 96, 391a.
28. Ratei, R., Matylis, A., Krahl, D., Arnold, R., Stein, H., Dorken, B. & Ludwig, W.D. (2000) Salvage therapy for relapsed mediastinal B-cell lymphoma with allogeneic HLA-identical related donor bone marrow transplantation, donor lymphocyte infusion and IDEC-C2B8. Leukemia and Lymphoma, 40, 133-140.
29. Robinson, S.P., Goldstone, A.H., Mackinnon, S., Carella, A., Russell, N., de Elvira, C.R., Taghipour, G. & Schmitz, N. (2002) Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood, 100, 4310-4316.
30. Saikia, T.K., Menon, H. & Advani, S.H. (2001) Prolonged neutropenia following anti CD20 therapy in a patient with relapsed follicular non-Hodgkin's lymphoma and corrected with IVIG. Annals of Oncology, 12, 1493-1494.
31. Schultz, K.R., Paquet, J., Bader, S. & HayGlass, K.T. (1995) Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease. Bone Marrow Transplantation, 16, 289-295.
32. Shipp, M.A., Abeloff, M.D., Antman, K.H., Carroll, G., Hagenbeek, A., Loeffler, M., Montserrat, E., Radford, J.A., Salles, G., Schmitz, N., Symann, M., Armitage, J.O., Philip, T. & Coiffler, B. (1999) International Consensus Conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury. Journal of Clinical Oncology, 17, 423-429.
33. Tsai, D.E., Moore, H., Hardy, C., Porter, D., Loh, E., Vaughn, D., Luger, S., Schuster, S. & Stadtmauer, E. (1999) Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transphmtation. Bone Marrow Transplantation, 24, 521-526.
34. Vose, J.M., Zhang, M.J., Rowlings, P.A., Lazarus, H.M., Bolwell, B.J., Freytes, C.O., Pavlovsky, S., Keating, A., Yanes, B., van Besien, K., Armitage, J.O. & Horowitz, M.M. (2001) Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report trom the Autologous Blood and Marrow Transplant Registry. Journal of Clinical Oncology, 19, 406-413.